Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PEP kicked off Q2 2026 earnings season today before the bell. Markets are watching closely. The S&P 500's opening direction hinges partly on the PepsiCo print. DAL reports tomorrow. BAC and JNJ follow next week. The big-cap earnings conveyor belt is now moving.
The $110 billion merger between PSKY and WBD has stalled again. Oregon regulators want 60 more days to review the deal. The DOJ has already approved it. But state-level scrutiny is adding drag. Options flow is reflecting deal risk. Bears are circling both names.
CHWY short interest hit 75.4% of free float — up 5.6 points in a week. CRWV climbed to 32.7% as AI skeptics build positions. WOLF remains the most extreme read at 116.7%. Some covering emerged at CAR, where Avis Budget's SI fell 3.2 points to 36.2%.
FSLR was the week's analyst winner. Its consensus target edged higher to $251.26. INTU took the biggest cut — target dropped to $484.73 amid AI competition fears in tax software. NFLX also saw a modest trim.
AZN fell after its CARDIO-TTRansform Phase III trial for Wainua failed to meet its primary endpoint. That's a setback for its cardiovascular pipeline. In London, the FCA charged a solicitor with insider trading related to the Seraphine sale — a reminder that regulatory enforcement is active on both sides of the Atlantic.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
